TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

Courtney A. Crane, Seunggu (Jude) Han, Jeffery J. Barry, Brian J. Ahn, Lewis L. Lanier, Andrew T. Parsa

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

The activating receptor NKG2D, expressed by natural killer (NK) cells and CD8+ T cells, has a role in the specific killing of transformed cells. We examined NKG2D expression in patients with glioblastoma multiforme and found that NKG2D was downregulated on NK cells and CD8+ T cells. Expression of NKG2D on lymphocytes significantly increased following tumor resection and correlated with an increased ability to kill NKG2D ligand-positive tumor targets. Despite the presence of soluble NKG2D ligands in the sera of glioblastoma patients, NKG2D downregulation was primarily caused by tumor-derived tumor growth factor-β, suggesting that blocking of this cytokine may have therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)7-13
Number of pages7
JournalNeuro-Oncology
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

NK Cell Lectin-Like Receptor Subfamily K
Glioma
Natural Killer Cells
Down-Regulation
T-Lymphocytes
Glioblastoma
Neoplasms
Ligands
Intercellular Signaling Peptides and Proteins
Lymphocytes
Cytokines
Serum

Keywords

  • GBM
  • Immune escape NKG2D
  • NK cell
  • TGF-β

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. / Crane, Courtney A.; Han, Seunggu (Jude); Barry, Jeffery J.; Ahn, Brian J.; Lanier, Lewis L.; Parsa, Andrew T.

In: Neuro-Oncology, Vol. 12, No. 1, 01.01.2010, p. 7-13.

Research output: Contribution to journalArticle

Crane, Courtney A. ; Han, Seunggu (Jude) ; Barry, Jeffery J. ; Ahn, Brian J. ; Lanier, Lewis L. ; Parsa, Andrew T. / TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. In: Neuro-Oncology. 2010 ; Vol. 12, No. 1. pp. 7-13.
@article{494b4691ef634479b0a4082bd6421980,
title = "TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients",
abstract = "The activating receptor NKG2D, expressed by natural killer (NK) cells and CD8+ T cells, has a role in the specific killing of transformed cells. We examined NKG2D expression in patients with glioblastoma multiforme and found that NKG2D was downregulated on NK cells and CD8+ T cells. Expression of NKG2D on lymphocytes significantly increased following tumor resection and correlated with an increased ability to kill NKG2D ligand-positive tumor targets. Despite the presence of soluble NKG2D ligands in the sera of glioblastoma patients, NKG2D downregulation was primarily caused by tumor-derived tumor growth factor-β, suggesting that blocking of this cytokine may have therapeutic benefit.",
keywords = "GBM, Immune escape NKG2D, NK cell, TGF-β",
author = "Crane, {Courtney A.} and Han, {Seunggu (Jude)} and Barry, {Jeffery J.} and Ahn, {Brian J.} and Lanier, {Lewis L.} and Parsa, {Andrew T.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1093/neuonc/nop009",
language = "English (US)",
volume = "12",
pages = "7--13",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

AU - Crane, Courtney A.

AU - Han, Seunggu (Jude)

AU - Barry, Jeffery J.

AU - Ahn, Brian J.

AU - Lanier, Lewis L.

AU - Parsa, Andrew T.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The activating receptor NKG2D, expressed by natural killer (NK) cells and CD8+ T cells, has a role in the specific killing of transformed cells. We examined NKG2D expression in patients with glioblastoma multiforme and found that NKG2D was downregulated on NK cells and CD8+ T cells. Expression of NKG2D on lymphocytes significantly increased following tumor resection and correlated with an increased ability to kill NKG2D ligand-positive tumor targets. Despite the presence of soluble NKG2D ligands in the sera of glioblastoma patients, NKG2D downregulation was primarily caused by tumor-derived tumor growth factor-β, suggesting that blocking of this cytokine may have therapeutic benefit.

AB - The activating receptor NKG2D, expressed by natural killer (NK) cells and CD8+ T cells, has a role in the specific killing of transformed cells. We examined NKG2D expression in patients with glioblastoma multiforme and found that NKG2D was downregulated on NK cells and CD8+ T cells. Expression of NKG2D on lymphocytes significantly increased following tumor resection and correlated with an increased ability to kill NKG2D ligand-positive tumor targets. Despite the presence of soluble NKG2D ligands in the sera of glioblastoma patients, NKG2D downregulation was primarily caused by tumor-derived tumor growth factor-β, suggesting that blocking of this cytokine may have therapeutic benefit.

KW - GBM

KW - Immune escape NKG2D

KW - NK cell

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=75749136051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749136051&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nop009

DO - 10.1093/neuonc/nop009

M3 - Article

VL - 12

SP - 7

EP - 13

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -